

MoleRNA – DISCOVERING AND DESIGNING SMALL MOLECULES TARGETING mRNA

molecule


Żwirki i Wigury 101
02-089 Warsaw

RNA LEADERS
EUROPE CONGRESS
Basel, Switzerland
15-16 March 2023


Irina Tuszyńska, Martyna Nowacka, Roman Błaszczak, Julita Nowicka, Nithin Chandran, Dorota Niedziałek, Grzegorz Wieczorek, Sławomir Bojarowski, Anna Antosiewicz, Katarzyna Głuchowska, Katarzyna Piwowar, Katarzyna Drzewicka, Angelika Muchowicz, Aleksandra Cupriak, Jacek Olczak, Zbigniew Zasłona

Background

Many undruggable proteins play key roles in the development and pathology of various diseases. Our strategy is to target mRNAs which encode these proteins. We utilize the fact that mRNAs adopt specific 3D structures which are integral and essential for their biological functions, specifically translation. We start with a structural biology approach and recognize defined motifs in the regulatory regions of mRNA. Subsequently, we aim at the identification of small molecules which by binding mRNA functional motifs modulate target protein levels. Our company has over 10 years of experience in the development of first-in-class drugs into clinic. For this project, within Molecule, we have created MoleRNA, a platform supported by *in silico* and wet lab analyses for designing small molecules targeting functional mRNA regions with defined structures. MoleRNA's objective is to develop lead compounds targeting mRNAs with optimized drug-like properties for undruggable proteins.



MoleRNA platform discovery workflow




Druggable regions selection


Predicted secondary structures are validated by SHAPE-MaP (*in vitro*, *in cellulo*) and structure conservation

Functional role of selected region is validated in biophysical and cellular assays


Prediction of the off-targets probability



Virtual screening pipeline



Wet lab screening cascade



Conclusions

To develop and test the MoleRNA pipeline, six structural motifs from different mRNAs were selected by *in silico* methods and validated in the wet lab, three of them entered virtual screening and high-throughput screening cascade. The identified hits will be checked in binding and cellular assays, and then to obtain a lead they will go through the optimization procedure.

Acknowledgements:

We thank Janusz Bujnicki, Joanna Sztuba-Solińska and Michael T. Wolfinger for scientific discussions and a fruitful collaboration. NGS was performed thanks to Genomics Core Facility CeNT UW, using NovaSeq 6000 platform financed by Polish Ministry of Science and Higher Education (decision no. 6817/IA/SP/2018 of 2018-04-10)

